

Amendments to the claims are reflected in the Listing of the Claims, which begins on page 2.

Remarks begin on page 8 of this paper.

In the Specification

Please replace the paragraph filed February 22, 2002 in a preliminary amendment for page 1 of the specification beginning at line 10 with the substitute paragraph as follows:

Cross Reference to Related Applications

This application is a continuation of and claims priority from United States Patent Application Serial No. 08/948,476 filed December 3, 1997 which claims benefit of provisional patent application 60/032,329 filed December 3, 1996, the entire contents of each application is incorporated herein in its entirety and without disclaimer.

In the Claims

Please cancel claims 1-35 without prejudice and without disclaimer. Applicants reserve the right to refile the claims in a continuing application.

The Listing of the Claims will replace all prior versions. No new matter has been added or introduced by these amendments to the claims.

LISTING OF THE CLAIMS

1-35. (canceled)

36. (New) An isolated polypeptide comprising SEQ ID NO:2.

37. (New) An isolated polypeptide that is at least 95% identical to corresponding consecutive amino acids of SEQ ID NO:2 and exhibits GIP antagonist activity.